Sunesis Pharmaceuticals (SNSS) Shares are Up 12.2%

Sunesis Pharmaceuticals (SNSS) : Traders are bullish on Sunesis Pharmaceuticals (SNSS) as it has outperformed the S&P 500 by a wide margin of 41.86% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 12.94%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.2% in the last 1 week, and is up 41.56% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 30.58% and the fifty day Moving Average is 53.81%. Sunesis Pharmaceuticals, Inc. is up 95.66% in the last three month period. Year-to-Date the stock performance stands at 2.51%.


Sunesis Pharmaceuticals (NASDAQ:SNSS): stock turned positive on Friday. Though the stock opened at $0.94, the bulls momentum made the stock top out at $1.05 level for the day. The stock recorded a low of $0.8851 and closed the trading day at $0.92, in the green by 3.36%. The total traded volume for the day was 4,175,413. The stock had closed at $0.8901 in the previous days trading.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Companys program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Brutons tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.